DVA 📈 DaVita HealthCare Partners - Overview
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US23918K1088
DVA: Kidney Dialysis, Lab Services, Hemodialysis, Clinical Research, Physician Services
DaVita Inc. is a leading provider of kidney dialysis services, catering to patients with chronic kidney failure in the United States. The company's extensive network of outpatient dialysis centers offers a range of services, including hemodialysis, which can be administered on an outpatient, hospital inpatient, or home-based basis. Additionally, DaVita operates clinical laboratories that conduct routine laboratory tests for dialysis patients, as well as other physician-prescribed tests for individuals with end-stage renal disease (ESRD). The company's management and administrative services support the efficient operation of outpatient dialysis centers, ensuring that patients receive high-quality care.
DaVita's service portfolio extends beyond dialysis, with the company offering integrated care and disease management services to patients participating in risk-based and other integrated care arrangements. This comprehensive approach enables patients to receive coordinated care, addressing their unique needs and promoting better health outcomes. Furthermore, DaVita engages in clinical research programs, providing valuable insights into the management of kidney disease and related conditions. The company's physician services and comprehensive kidney care services round out its offerings, making it a one-stop solution for patients requiring kidney care. DaVita also provides acute inpatient dialysis services, related laboratory services, and operates a transplant software business, underscoring its commitment to delivering a broad spectrum of kidney care services.
With a history dating back to 1994, DaVita Inc. has established itself as a prominent player in the healthcare industry, particularly in the realm of kidney care. The company's name change from DaVita HealthCare Partners Inc. to DaVita Inc. in September 2016 reflects its evolving focus and commitment to delivering high-quality patient care. Headquartered in Denver, Colorado, DaVita Inc. is a publicly traded company, listed on the New York Stock Exchange (NYSE) under the ticker symbol DVA. Its common stock is classified under the GICS Sub Industry of Health Care Services, with the ISIN code US23918K1088. For more information, investors and patients can visit the company's website at https://www.davita.com.
Additional Sources for DVA Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
DVA Stock Overview
Market Cap in USD | 12,528m |
Sector | Healthcare |
Industry | Medical Care Facilities |
GiC Sub-Industry | Health Care Services |
IPO / Inception | 1995-10-31 |
DVA Stock Ratings
Growth 5y | 59.2% |
Fundamental | 46.0% |
Dividend | - |
Rel. Strength Industry | 798 |
Analysts | 3.11/5 |
Fair Price Momentum | 160.06 USD |
Fair Price DCF | 448.24 USD |
DVA Dividends
No Dividends PaidDVA Growth Ratios
Growth Correlation 3m | -25.6% |
Growth Correlation 12m | 90.6% |
Growth Correlation 5y | 44.6% |
CAGR 5y | 15.35% |
CAGR/Mean DD 5y | 0.92 |
Sharpe Ratio 12m | 1.28 |
Alpha | 23.37 |
Beta | 0.82 |
Volatility | 29.09% |
Current Volume | 1793.3k |
Average Volume 20d | 738.7k |
As of December 22, 2024, the stock is trading at USD 151.85 with a total of 1,793,318 shares traded.
Over the past week, the price has changed by -0.58%, over one month by -5.92%, over three months by -7.41% and over the past year by +46.19%.
Partly, yes. Based on ValueRay Fundamental Analyses, DaVita HealthCare Partners (NYSE:DVA) is currently (December 2024) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 46.00 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of DVA as of December 2024 is 160.06. This means that DVA is currently overvalued and has a potential downside of 5.41%.
DaVita HealthCare Partners has received a consensus analysts rating of 3.11. Therefor, it is recommend to hold DVA.
- Strong Buy: 1
- Buy: 1
- Hold: 5
- Sell: 2
- Strong Sell: 0
According to ValueRays Forecast Model, DVA DaVita HealthCare Partners will be worth about 172.9 in December 2025. The stock is currently trading at 151.85. This means that the stock has a potential upside of +13.84%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 156.9 | 3.3% |
Analysts Target Price | 113 | -25.6% |
ValueRay Target Price | 172.9 | 13.8% |